Concord Biotech Limited (NSE:CONCORDBIO)

Market Cap	189.20B
Revenue (ttm)	12.00B
Net Income (ttm)	3.72B
Shares Out	104.62M
EPS (ttm)	35.52
PE Ratio	50.91
Forward PE	41.73
Dividend	10.70 (0.59%)
Ex-Dividend Date	n/a

Volume	124,821
Average Volume	217,019
Open	1,800.60
Previous Close	1,808.50
Day's Range	1,781.00 - 1,822.00
52-Week Range	1,345.00 - 2,664.00
Beta	n/a
RSI	46.69
Earnings Date	Aug 13, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 1,377
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CONCORDBIO

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.